SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Injection Formulation

Version 7.0  Revision Date: 22.03.2021  SDS Number: 27567-00019  Date of last issue: 16.10.2020

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Temozolomide Injection Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company: MSD
Piercetown
A86 HD21 Dunboyne, Ireland
Telephone: 908-740-4000
E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Acute toxicity, Category 3 H301: Toxic if swallowed.
Eye irritation, Category 2 H319: Causes serious eye irritation.
Germ cell mutagenicity, Category 2 H341: Suspected of causing genetic defects.
Carcinogenicity, Category 2 H351: Suspected of causing cancer.
Reproductive toxicity, Category 1B H360FD: May damage fertility. May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 2 H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms:

Signal word: Danger
Hazard statements:
H301: Toxic if swallowed.
H319: Causes serious eye irritation.
H341: Suspected of causing genetic defects.
H351: Suspected of causing cancer.
Precautionary statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P260 Do not breathe dust.
- P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
- P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. Rinse mouth.
- P308 + P313 IF exposed or concerned: Get medical advice/ attention.
- P337 + P313 If eye irritation persists: Get medical advice/ attention.

**Hazardous components which must be listed on the label:**
- Temozolomide

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients**

**3.2 Mixtures Components**

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citric acid</td>
<td>77-92-9</td>
<td>Eye Irrit. 2; H319</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td></td>
<td>201-069-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temozolomide</td>
<td>85622-93-1</td>
<td>Acute Tox. 2; H300</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Muta. 2; H341 Carc. 2; H351</td>
<td></td>
</tr>
</tbody>
</table>
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of an accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Call a physician or poison control centre immediately. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Toxic if swallowed. Causes serious eye irritation. Suspected of causing genetic defects. Suspected of causing cancer. May damage fertility. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.

Contact with dust can cause mechanical irritation or drying of the skin.
4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Metal oxides
Chlorine compounds

5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe dust.
- Do not swallow.
- Do not get in eyes.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the
use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
- Strong oxidizing agents
- Organic peroxides
- Explosives
- Gases

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Occupational Exposure Limits</th>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temozolomide</td>
<td>85622-93-1</td>
<td>TWA</td>
<td>0.1 µg/m3 (OEB 5)</td>
<td>Internal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wipe limit</td>
<td>1 µg/100 cm2</td>
<td>Internal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>2068.62 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>2068.62 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>443.28 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>443.28 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Acute systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Injection Formulation

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citric acid</td>
<td>Fresh water</td>
<td>0.44 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.044 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>1000 mg/l</td>
</tr>
<tr>
<td>Fresh water sediment</td>
<td></td>
<td>34.6 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Marine sediment</td>
<td></td>
<td>3.46 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Soil</td>
<td></td>
<td>33.1 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>Fresh water</td>
<td>5 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>500 mg/l</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>4.86 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
No open handling permitted.
Totally enclosed processes and materials transport systems are required.
Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment
Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Skin and body protection
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to I.S. EN 143
Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Injection Formulation

Physical state: powder
Colour: white
Odour: No data available
Odour Threshold: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Flash point: Not applicable
Auto-ignition temperature: No data available
Decomposition temperature
Decomposition temperature: No data available
pH: No data available
Viscosity
Viscosity, kinematic: Not applicable
Solubility(ies)
Water solubility: soluble
Partition coefficient: n-octanol/water: Not applicable
Vapour pressure: Not applicable
Relative density: No data available
Density: No data available
Relative vapour density: Not applicable
Particle characteristics
Particle size: No data available

9.2 Other information
Explosives: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Evaporation rate : Not applicable
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Toxic if swallowed.

Product:
Acute oral toxicity : Acute toxicity estimate: 243.59 mg/kg
Method: Calculation method

Components:

Citric acid:
Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity
Temozolomide Injection Formulation

**Acute oral toxicity**
LD50 (Dog): 19 mg/kg
LD50 (Rat): 315 mg/kg
LD50 (Mouse): 205 mg/kg

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Citric acid:**
- **Species:** Rabbit
- **Method:** OECD Test Guideline 404
- **Result:** No skin irritation

**Serious eye damage/eye irritation**
Causes serious eye irritation.

**Components:**

**Citric acid:**
- **Species:** Rabbit
- **Method:** OECD Test Guideline 405
- **Result:** Irritation to eyes, reversing within 21 days

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

**Temozolomide:**
- **Test Type:** Maximisation Test
- **Exposure routes:** Dermal
- **Species:** Guinea pig
- **Result:** negative

**Germ cell mutagenicity**
Suspected of causing genetic defects.

**Components:**

**Citric acid:**
- **Genotoxicity in vitro:** Test Type: Bacterial reverse mutation assay (AMES)
  - **Result:** negative
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Injection Formulation

Version 7.0  Revision Date: 22.03.2021  SDS Number: 27567-00019  Date of last issue: 16.10.2020  Date of first issue: 03.11.2014

Test Type: in vitro micronucleus test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo:
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Temozolomide:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: positive

Test Type: Chromosome aberration test in vitro
Test system: Human lymphocytes
Result: positive

Germ cell mutagenicity - Assessment:
Positive results from in vitro mammalian mutagenicity assays, chemical structure activity relationship to known germ cell mutagens

Carcinogenicity
Suspected of causing cancer.

Components:

Temozolomide:
Species: Rat
Application Route: Oral
Exposure time: 6 Months
Result: positive
Target Organs: Mammary gland

Carcinogenicity - Assessment:
Limited evidence of carcinogenicity in animal studies

Reproductive toxicity
May damage fertility. May damage the unborn child.

Components:

Citric acid:
Effects on foetal development:
Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Temozolomide:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 8.5 mg/kg body weight
Result: positive

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 13 mg/kg body weight
Result: positive, Malformations were observed.

Reproductive toxicity - Assessment: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments. Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

**Temozolomide:**
- Exposure routes: Ingestion
- Target Organs: Bone marrow, thymus gland, Lymph nodes, spleen
- Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

**Citric acid:**
- Species: Rat
- NOAEL: 4,000 mg/kg
- LOAEL: 8,000 mg/kg
- Application Route: Ingestion
- Exposure time: 10 Days

**Temozolomide:**
- Species: Rat, female
- NOAEL: 4 mg/kg
- LOAEL: 21 mg/kg
- Application Route: Oral
- Exposure time: 6 Months
- Target Organs: Lymph nodes, thymus gland, Bone marrow, Reproductive organs

- Species: Rat, male
- NOAEL: 8.5 mg/kg
- LOAEL: 34 mg/kg
Temozolomide Injection Formulation

Application Route: Oral
Exposure time: 6 Months
Target Organs: Lymph nodes, thymus gland, Bone marrow, male reproductive organs, Gastrointestinal tract

Species: Dog
NOAEL: 2.5 mg/kg
LOAEL: 6.3 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Bone marrow, spleen, male reproductive organs, Gastrointestinal tract, thymus gland

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:
Temozolomide:
Ingestion: Symptoms: Blood disorders, Nausea, Vomiting, Diarrhoea, anorexia, Fatigue, hair loss

SECTION 12: Ecological information

12.1 Toxicity

Components:
Citric acid:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 1,535 mg/l Exposure time: 24 h

Temozolomide:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
## Toxicity to daphnia and other aquatic invertebrates

| EC50 (Daphnia magna (Water flea)) | > 100 mg/l |
| Exposure time | 48 h |
| Method | OECD Test Guideline 202 |

## Toxicity to algae/aquatic plants

| EC50 (Pseudokirchneriella subcapitata (green algae)) | > 90 mg/l |
| Exposure time | 72 h |
| Method | OECD Test Guideline 201 |

| NOEC (Pseudokirchneriella subcapitata (green algae)) | 40 mg/l |
| Exposure time | 72 h |
| Method | OECD Test Guideline 201 |

## Toxicity to microorganisms

| EC50 | > 100 mg/l |
| Exposure time | 3 h |
| Test Type | Respiration inhibition |
| Method | OECD Test Guideline 209 |

### 12.2 Persistence and degradability

#### Components:

- **Citric acid**
  - Biodegradability: Result: Readily biodegradable.
  - Biodegradation: 97 %
  - Exposure time: 28 d
  - Method: OECD Test Guideline 301B

- **Temozolomide**
  - Biodegradability: Result: rapidly degradable
  - Biodegradation: 83 %
  - Exposure time: 35 d
  - Stability in water: Degradation half life (DT50): < 1 d

### 12.3 Bioaccumulative potential

#### Components:

- **Citric acid**
  - Partition coefficient: n-octanol/water: log Pow: -1.72

- **Temozolomide**
  - Partition coefficient: n-octanol/water: log Pow: 1.35

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

**Product:**
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Injection Formulation

Version           SDS Number:         Date of last issue: 16.10.2020
7.0               27567-00019        Date of first issue: 03.11.2014

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Remarks : Not applicable for product as supplied.
SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

- REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
- REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
- REACH - List of substances subject to authorisation (Annex XIV): Not applicable
- Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
- Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
- Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

Other regulations:
- Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
- Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
- AICS: not determined
- DSL: not determined
- IECSC: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

- H300: Fatal if swallowed.
- H319: Causes serious eye irritation.
- H341: Suspected of causing genetic defects.
- H351: Suspected of causing cancer.
- H360FD: May damage fertility. May damage the unborn child.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Injection Formulation

Version 7.0 Revision Date: 22.03.2021 SDS Number: 27567-00019 Date of last issue: 16.10.2020 Date of first issue: 03.11.2014

H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations
Acute Tox. : Acute toxicity
Carc. : Carcinogenicity
Eye Irrit. : Eye irritation
Muta. : Germ cell mutagenicity
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECS - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture:

| Acute Tox. 3 | H301 |
| Eye Irrit. 2 | H319 |
| Muta. 2 | H341 |

Classification procedure:
Calculation method
# Temozolomide Injection Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.0</td>
<td>22.03.2021</td>
<td>27567-00019</td>
<td>16.10.2020</td>
<td>03.11.2014</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Carc. 2</th>
<th>Repr. 1B</th>
<th>STOT RE 2</th>
<th>Calculation method</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>H351</td>
<td>H360FD</td>
<td>H373</td>
<td></td>
</tr>
</tbody>
</table>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN